Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV

Clinical Cancer Research

Volumn 18, Issue 18, 2012, Pages 4931-4941

  Yoo, Ji Young ^a   Pradarelli, Jason ^a,b   Haseley, Amy ^a   Wojton, Jeffrey ^a   Kaka, Azeem ^a   Bratasz, Anna ^a,b   Alvarez Breckenridge, Christopher A ^a   Yu, Jun Ge ^b   Powell, Kimerly ^a,b   Mazar, Andrew P ^b   Teknos, Theodoros N ^c   Chiocca, E Antonio ^a   Glorioso, Joseph C ^d   Old, Matthew ^c   Kaur, Balveen ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE TETRATHIOMOLYBDATE; COPPER; ONCOLYTIC HERPES VIRUS; RQNESTIN34.5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL DENSITY; BLOOD VESSEL PARAMETERS; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CELL KILLING; CHELATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG STABILITY; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL TIME; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHELATING AGENTS; COMBINED MODALITY THERAPY; COPPER; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; GENETIC THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; MICE; MICE, NUDE; MOLYBDENUM; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SIMPLEXVIRUS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866392791     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0697     Document Type: Article

References (42)

1. Wollmann G, Ozduman K, van den Pol AN. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J 2012;18:69-81.
2. Cassady KA, Parker JN. Herpesvirus vectors for therapy of brain tumors. Open Virol J 2010;4:103-8.
3. Kaur B, Chiocca EA, Cripe TP. Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol 2011 Jul 8. [Epub ahead of print].
4. Kurozumi K, Hardcastle J, Thakur R, Shroll J, Nowicki M, Otsuki A, et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 2008;16:1382-91.
5. Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 2007;67:440-4.
6. Libertini S, Iacuzzo I, Perruolo G, Scala S, Ierano C, Franco R, et al. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res 2008;14:6505-14.
7. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007;99:1768-81.
8. Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther 2008;16:1041-7.
9. Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Waterman P, et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 2010;18:285-94.
10. Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang J, Powell K, et al. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther 2012;20:287-97.
11. Israyelyan A, Shannon EJ, Baghian A, Kearney MT, Kousoulas KG. Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn. Cancer Chemother Pharmacol 2009;64:1201-10.
12. Hu GF. Copper stimulates proliferation of human endothelial cells under culture. J Cell Biochem 1998;69:326-35.
13. Soncin F, Guitton JD, Cartwright T, Badet J. Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells. Biochem Biophys Res Commun 1997;236:604-10.
14. Turecky L, Kalina P, Uhlikova E, Namerova S, Krizko J. Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin Wochenschr 1984;62:187-9.
15. Clewell A, Barnes M, Endres JR,Ahmed M,GhambeerDK. Efficacy and tolerability assessment of a topical formulation containing copper sulfate and hypericum perforatum on patientswith herpes skin lesions: a comparative, randomized controlled trial. J Drugs Dermatol 2012;11:209-15.
16. Panteva M, Varadinova T, Turel I. Effect of copper acyclovir complexes on herpes simplex virus type 1 and type 2 (HSV-1, HSV-2) infection in cultured cells. Met Based Drugs 1998;5:19-23.
17. Shishkov S, Varadinova T, Panteva M, Bontchev P. Effect of complexes of zinc, cobalt and copper with d-aminosugars on the replication of herpes simplex virus type 1 (HSV-1). Met Based Drugs 1997;4:35-8.
18. Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002;62:4854-9.
19. Kumar P, Yadav A, Patel SN, Islam M, Pan Q, Merajver SD, et al. Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. Mol Cancer 2010;9:206.
20. Pan Q, Rosenthal DT, Bao L, Kleer CG, Merajver SD. Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic remodeling of the mammary gland. Clin Cancer Res 2009;15:7441-6.
21. Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, et al. A noncomparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naive prostate cancer. Urol Oncol 2011 Aug 2. [Epub ahead of print].
22. Dmitrieva N, Yu L, Viapiano M, Cripe TP, Chiocca EA, Glorioso JC, et al. Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy. Clin Cancer Res 2011;17:1362-72.
23. Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005;65:2832-9.
24. Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 2006;13:705-14.
25. Sundaresan P, Hunter WD, Martuza RL, Rabkin SD. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 2000;74:3832-41.
26. Sagripanti JL, Routson LB, Bonifacino AC, Lytle CD. Mechanism of copper-mediated inactivation of herpes simplex virus. Antimicrob Agents Chemother 1997;41:812-7.
27. Haseley A, Boone S, Wojton J, Yu L, Yoo JY, Yu J, et al. Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Res 2012;72:1353-62.
28. Wakimoto H, Ikeda K, Abe T, Ichikawa T, Hochberg FH, Ezekowitz RA, et al. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther 2002;5:275-82.
29. Hassouneh B, Islam M, Nagel T, Pan Q, Merajver SD, Teknos TN. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther 2007;6:1039-45.
30. Schmidt C. Amgen spikes interest in live virus vaccines for hard-to-treat cancers. Nat Biotechnol 2011;29:295-6.
31. Smith E, Breznik J, Lichty BD. Strategies to enhance viral penetration of solid tumors. Hum Gene Ther 2011;22:1053-60.
32. Sen CK, Khanna S, Venojarvi M, Trikha P, Ellison EC, Hunt TK, et al. Copper-induced vascular endothelial growth factor expression and wound healing. Am J Physiol Heart Circ Physiol 2002;282:H1821-7.
33. Rajalingam D, Kumar TK, Yu C. The C2A domain of synaptotagmin exhibits a high binding affi nity for copper: implications in the formation of the multiprotein FGF release complex. Biochemistry 2005;44:14431-42.
34. Martin F, Linden T, Katschinski DM, Oehme F, Flamme I, Mukhopadhyay CK, et al. Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood 2005;105:4613-9.
35. Bar-Or D, Thomas GW, Yukl RL, Rael LT, Shimonkevitz RP, Curtis CG, et al. Copper stimulates the synthesis and release of interleukin-8 in human endothelial cells: a possible early role in systemic inflammatory responses. Shock 2003;20:154-8.
36. Yoshida D, Ikeda Y, Nakazawa S. Quantitative analysis of copper, zinc and copper/zinc ratio in selected human brain tumors. J Neurooncol 1993;16:109-15.
37. Brem SS, Zagzag D, Tsanaclis AM, Gately S, Elkouby MP, Brien SE. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol 1990;137:1121-42.
38. Brem S, Grossman SA, Carson KA, New P, Phuphanich S, Alavi JB, et al. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol 2005;7:246-53.
39. Lowndes SA, Sheldon HV, Cai S, Taylor JM, Harris AL. Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms. Microvasc Res 2009;77:314-26.
40. Juarez JC, Betancourt O Jr., Pirie-Shepherd SR, Guan X, Price ML, Shaw DE, et al. Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res 2006;12:4974-82.
41. Lowndes SA, Adams A, Timms A, Fisher N, Smythe J, Watt SM, et al. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res 2008;14:7526-34.
42. Sagripanti JL, Routson LB, Lytle CD. Virus inactivation by copper or iron ions alone and in the presence of peroxide. Appl Environ Microbiol 1993;59:4374-6.